CPRIT Awards Emtora Biosciences $3 Million Grant to Develop Investigational Familial Adenomatous Polyposis Drug
source: pixabay.com

CPRIT Awards Emtora Biosciences $3 Million Grant to Develop Investigational Familial Adenomatous Polyposis Drug

According to a recent press release, Texas-based biotechnology company Emtora Biosciences was chosen earlier this month to receive a $3 million grant from the Cancer Prevention and Research Institute of…

Continue Reading CPRIT Awards Emtora Biosciences $3 Million Grant to Develop Investigational Familial Adenomatous Polyposis Drug
This Just in: Data from Phase 3 Trial for Familial Adenomatous Polyposis is Coming Early 2019
Source: Pixabay.com

This Just in: Data from Phase 3 Trial for Familial Adenomatous Polyposis is Coming Early 2019

Familial adenomatous polyposis (FAP) is a condition which causes extra tissue to form in various parts of the body such as the large intestine and gastrointestinal track. FAP affects about…

Continue Reading This Just in: Data from Phase 3 Trial for Familial Adenomatous Polyposis is Coming Early 2019

FDA Fast Tracks First Possible Treatment for Familial Adenomatous Polyposis

In late September, Food and Drug Administration designated "fast track" status to the research and development of CPP-1X/sul for adults diagnosed with Familial Adenomatous Polyposis (FAP). Overseeing the project are Cancer…

Continue Reading FDA Fast Tracks First Possible Treatment for Familial Adenomatous Polyposis
Close Menu